© 2024 SEISMIC TX. ALL RIGHTS RESERVED.
WATERTOWN, Mass., June 25, 2024 — Seismic Therapeutic, Inc., the machine learning immunology company, today announced the appointment of Brendan St. Amant as General Counsel and a member of the company’s leadership team. Mr. St. Amant brings more than 16 years of combined law firm and in-house experience across a range of areas, including corporate governance, securities and disclosure matters, regulatory and corporate compliance, business development and financing transactions, general business law, and managing legal and intellectual property functions at public and private biotechnology companies.
“We are delighted to welcome Brendan to the Seismic leadership team. He joins us at a time when we are rapidly evolving into a clinical-stage company, and his business skills and legal expertise will be highly valuable as we make progress toward important clinical and business milestones,” said Jo Viney, PhD, Co-Founder, President and CEO of Seismic. “Brendan has an outstanding track record as a business leader and legal expert, and his background at biotechnology companies is ideally suited to further strengthen our business excellence and help Seismic capture the tremendous opportunities ahead of us.”
“I am thrilled to join Seismic’s exceptional team and culture at a time when the company has such positive momentum in advancing its pipeline and business,” said Brendan St. Amant. “I look forward to collaborating with the leadership team to help Seismic achieve its goal of creating next generation immunology drugs for patients.”
Prior to joining Seismic, Brendan was General Counsel and Corporate Secretary for Synlogic, Inc., a publicly traded biotech company with a phase 3 clinical drug program. Previously, he was Vice President, Legal, and member of the leadership team at Ohana Biosciences and was senior counsel at Vertex Pharmaceuticals. Brendan was a partner at the law firm of Donnelly, Conroy & Gelhaar, LLP, in Boston where he focused on complex commercial controversies and government enforcement. Earlier in his legal career, Brendan served as a clerk for the Hon. Alvin W. Thompson, Chief, U.S. District Court for the District of Connecticut and was an associate at the law firm of Goodwin Procter. Brendan has served on several practice-related bar committees and on the executive committee of the Board of Trustees of the Massachusetts Continuing Legal Education corporation. He received his BA from Cornell University, JD from Harvard Law School, and his MPP from the Harvard Kennedy School.
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Emiley Demick, Precision AQ (formerly known as Stern IR)
212-362-1200
emiley.demick@precisionaq.com
Data to Highlight Machine Learning IMPACT Platform and Emerging Pipeline of Novel Therapeutics to Treat Autoimmune Diseases
Watertown, Mass., June 4, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced that the company will participate in three upcoming scientific conferences, presenting data on Seismic’s emerging pipeline of novel therapeutics to treat rare and prevalent autoimmune diseases, as well as its proprietary IMPACT platform that applies machine learning to biologics drug discovery. The company’s two lead drug candidates will be highlighted: S-1117, a novel pan-immunoglobulin (Ig) G protease addressing multiple pathogenic mechanisms in autoimmune disease, and S-4321, a PD-1 agonist:Fc gamma receptor IIb selective Dual-cell Bidirectional (DcB) antibody.
Details of Seismic’s presentations and poster sessions are as follows:
June 11-13 – Structure Based Drug Design Summit, Boston, MA
Presentation Title: Structure Empowered IMPACT Platform in the Discovery & Development of Immunoglobulin Sculpting (IgSc) Enzyme & Dual-Cell Bidirectional (DcB) Antibody Drugs for Immunological Diseases
Session: From Small Molecules to Peptides to Biologics: Dealing with Hard-to-Drug, Dynamic, Proteins with the Structural Biology Toolbox – Case Study Presentations
Date: Thursday, June 13
Time: 1:30 p.m. ET
Presenter: Yi Xing, PhD, Senior Director, Drug Creation
Poster Title: Structural Basis for Fc Domain Selectivity to FcgRIIB
Session: Afternoon Break & Poster Session
Date: Wednesday, June 12
Time: 3:00 p.m. ET
Presenter: Colin Lipper, PhD, Senior Scientist, Drug Creation
June 18-21 – Federation of Clinical Immunology Societies (FOCIS) 2024 Annual Meeting, San Francisco, CA
Poster Title: Identification and Characterization of PD-1 Agonists for the Treatment of Autoimmune and Inflammatory Diseases
Date: Tuesday, June 18
Time: 6:00-7:30 p.m. PT
Poster #: #1735385; Tu131
Presenter: Mike Cianci, M.S. Senior Associate Scientist
Poster Title: Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Date: Wednesday, June 19
Time: 1:00-5:00 p.m. PT
Poster #: #1735687; W121
Presenter: Ivan Mascanfroni, PhD, Senior Director, Immunology
June 23-26 – ESACT – European Society for Animal Cell Technology, Edinburgh, Scotland
Presentation Title: Mitigating Risk During Biologics Manufacturing Using Discovery Stage Developability Assays and State of the Art Machine Learning Based Optimization
Session: Session 2 – Transitioning from development to manufacture: How do science and innovation translate into highly efficient biomanufacturing?
Date: Wednesday, June 26
Time: 2:15-3:45 p.m. BST
Presenter: Jyothsna Visweswaraiah, PhD, Director, Drug Creation
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Emiley Demick, Precision AQ (formerly known as Stern IR)
212-362-1200
emiley.demick@precisionaq.com
Showcasing major shift in discovery and development of immunology therapies enabled by machine learning
Watertown, Mass., May 29, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced that company management will participate in the following June investor conferences:
Jefferies Global Healthcare Conference
Date: Tuesday, June 4, 2024
Location: New York, NY
Format: 1×1 meetings
Leerink Partners Biopharma Private Company Connect
Date: Tuesday, June 25 – Wednesday, June 26, 2024
Location: Virtual
Format: 1×1 meetings
Morgan Stanley 3rd Annual Life Sciences AI Summit
Date: Wednesday June 26 – Thursday, June 27, 2024
Location: New York, NY
Format: Panel and 1×1 meetings
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Emiley Demick, Precision AQ (formerly known as Stern IR)
212-362-1200
emiley.demick@precisionaq.com
Company’s lead pipeline program in IgG sculpting enzymes demonstrates rapid and sustained reduction of IgG levels and ability to address multiple pathogenic mechanisms
Preclinical findings support S-1117’s differentiated product profile and continued advancement towards clinical development
Watertown, Mass., April 12, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of preclinical data for its pan‑immunoglobulin G (IgG) sculpting enzyme candidate, S-1117, at the American Academy of Neurology (AAN) 2024 annual meeting in Denver. The poster presentation titled, “Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases,” features preclinical in vitro and in vivo results supporting the differentiated therapeutic profile of S-1117.
S-1117 is a novel engineered pan-IgG protease targeting IgG autoantibodies that have an important role in the pathogenesis of a range of chronic and acute autoantibody mediated diseases, including the chronic neuromuscular autoimmune disorder, myasthenia gravis.
“Given our pan-IgG sculpting enzyme’s ability to address multiple pathogenic mechanisms as a single drug agent, it has the potential to achieve improved clinical outcomes compared to current therapeutic approaches in chronic autoantibody-mediated diseases,” said Kevin Otipoby, PhD, Chief Research Officer of Seismic Therapeutic. “With the polypharmacology that is possible with S-1117, we aim to overcome existing treatment limitations and achieve higher rates of remission for patients with chronic autoantibody mediated diseases. We are excited to continue to advance S-1117 towards first-in-human clinical studies.”
The preclinical data presented at AAN describe results across a variety of measures that support the differentiated profile of S-1117 compared to therapeutic benchmarks in chronic autoantibody-mediated diseases. S-1117 addresses multiple mechanisms of autoimmunity, as shown by the preclinical results that demonstrated rapid and deep lowering of IgG and immune complex levels, reducing IgG effector functions, and cleaving the antigen B‑cell receptor (BCR) on memory B cells.
In vitro studies demonstrated S-1117’s ability to cleave soluble and membrane-bound forms of IgG, including the BCR, and to reduce tissue-damaging IgG effector functions:
In vivo studies performed in mouse models with S-1117 or Fc-fused pan-IgG protease progenitor molecule demonstrated the compound’s ability to lower pathogenic IgG and immune complex levels:
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Emiley Demick, Stern Investor Relations
212-362-1200
emiley.demick@sternir.com
Growing body of scientific evidence demonstrates productivity of IMPACT platform and rapidly expanding pipeline opportunity in immunology
Watertown, Mass., April 9, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced that the company will participate in four upcoming scientific conferences, presenting the company’s emerging pipeline of novel therapeutics to treat rare and prevalent autoimmune diseases, as well as its proprietary IMPACT platform that applies machine learning to biologics drug discovery.
“The bolus of preclinical data we are presenting in the coming months highlights the immense potential of Seismic’s pipeline in autoimmune diseases,” said Jo Viney, PhD, Founder, President and CEO of Seismic Therapeutic. “In just two years since the company’s founding, we have internally developed two potentially best-in-class development candidates as well as a number of discovery-stage programs, and these presentations from Seismic’s expert team of scientists underscore the productivity of our IMPACT platform in drug discovery. We look forward to progressing S-1117 and S-4321 through IND-enabling studies, as we work to deliver the next-generation of novel biologics to patients suffering from a variety of autoimmune diseases.”
Details of Seismic’s presentations and poster sessions are as follows:
April 16-18 – 4th Fc-Mediated Function Summit
Presentation Title: Fine-Tuning Antibody-Based Immunotherapy Identification & Characterization of FcγRIIb Selective PD-1 Agonist Antibodies to Treat Autoimmunity & Inflammation
Date: Wednesday, April 17
Time: 3:00 p.m. ET
Section: Targeting FcyR in its Own Right – What is the Next Mutation?
Presenter: Daniela Cipolletta, PhD, Senior Director of Immunology, Seismic Therapeutic
May 3-7 – IMMUNOLOGY2024™, Annual Meeting of the American Association of Immunologists
Poster Title: Identification and Characterization of PD-1 Agonists for the Treatment of Autoimmune and Inflammatory Diseases
Date: Monday, May 6
Time: 7:00 a.m. CT
Poster #: B887
Presenter: Maria Cecilia Ramello, PhD, Senior Scientist, Seismic Therapeutic
Poster Title: Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Date: Saturday, May 4
Time: 7:00 a.m. CT
Poster #: B859
Presenter: Ivan Mascanfroni, PhD, Senior Director of Immunology, Seismic Therapeutic
In addition to the poster presentations, Seismic management will participate in the following sessions at IMMUNOLOGY2024:
Session Title: Recent Breakthroughs and Emerging Therapeutic Strategies for Chronic Inflammatory and Fibrotic Disease
Session Presentation Title: The polypharmacology of dual cell bidirectional (DcB) agonist antibodies for treating autoimmunity
Date: Saturday, May 4
Time: 8:00 a.m. CT
Session Co-Chair & Presenter: Jo Viney, PhD, Founder, CEO and President, Seismic Therapeutic
Session Title: Therapeutic Intervention for Treating Immune Dysregulation in Inflammation and Cancer
Date: Sunday, May 5
Time: 4:30 p.m. CT
Co-Moderator: Ivan Mascanfroni, PhD, Senior Director of Immunology, Seismic Therapeutic
May 13-17 – 20th Annual PEGS Boston Summit
Presentation Title: Dual Cell Bidirectional Antibodies for Treating Autoimmunity
Session: Variety of mechanisms using bispecific antibodies
Date: Wednesday, May 15
Time: 3:00 p.m. ET
Presenter: Jyothsna Visweswaraiah, PhD, Director of Drug Creation, Seismic Therapeutic
Poster Title: Characterization of PD1 Agonizing Dual cell Bidirectional Antibodies to Treat Autoimmune Diseases
Presenter: Rasika Harshe, M.S., Senior Associate Scientist II, Seismic Therapeutic
Poster Title: Discovery and Characterization of FcγRIIb Selective Antibodies to Enhance Checkpoint Agonism and Treat Autoimmunity
Presenter: Ishan Sharma, M.S., Scientist, Seismic Therapeutic
Poster Title: Accelerating The Discovery Of A Pan-Igg Protease Using The IMPACT Platform
Presenter: Soumya Bengeri, M.S., Senior Associate Scientist, Seismic Therapeutic
Poster Title: Design and Screening of FcγRIIb Selective Fc Domains to Enhance Checkpoint Agonism and Treat Autoimmunity
Presenter: Samuel Perry, PhD, Senior Scientist, Seismic Therapeutic
May 21-23 – 6th Treg Directed Therapies Summit
Presentation Title: Integration of Treg Biology and Immunotherapy
Session Category: Exploring the Impact of Treg Biology on Development of Treg Directed Therapies to Drive Precise Therapeutic Interventions.
Date: Tuesday, May 21
Time: 12:00 p.m. ET
Presenter: Marisella Panduro, PhD, Principal Scientist, Seismic Therapeutic
Presentation Title: Inhibitory Receptor Targeting & Modulation of Treg Biology
Session Category: Non-Cell Based Approaches
Date: Thursday, May 23
Time: 11:30 a.m. ET
Presenter: Daniela Cipolletta, PhD, Senior Director of Immunology, Seismic Therapeutic
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Emiley Demick, Stern Investor Relations
212-362-1200
emiley.demick@sternir.com
Watertown, Mass., March 8, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced that the company will present preclinical data for its pan-immunoglobulin G (IgG) sculpting enzyme candidate, S-1117, at the American Academy of Neurology (AAN) annual meeting taking place on April 13-18 in Denver.
S-1117 is a novel engineered pan-IgG protease for the potential treatment of a range of chronic and acute autoantibody mediated diseases, including the chronic neuromuscular autoimmune disorder, myasthenia gravis. The presentation at the AAN annual meeting will outline key preclinical in vitro and in vivo results supporting the differentiated profile of S-1117 compared to therapeutic benchmarks in chronic autoantibody mediated diseases. S-1117 addresses multiple mechanisms of autoimmunity by lowering IgG and immune complex levels, reducing IgG effector functions and cleaving the antigen receptor (BCR) on memory B cells. Moreover, in a mouse pharmacokinetic model, S-1117 was able to achieve deep, sustained and rapid reduction in human IgG.
Presentation details:
Title: Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Session: P4 – Autoimmune Neurology: Peripheral Autoimmunity
Date: Monday, April 15, 2024
Time: 11:45 a.m. – 12:45 p.m. MT
Area: 14
Poster number: 018
Abstract number: 6869
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Funding will advance company’s two lead programs through clinical proof-of-mechanism, as well as enable continued growth of its biologics pipeline and expansion of its IMPACT platform
The financing brings total capital raised by the company to $222 million
Cambridge, Mass., December 4, 2023 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced that it has closed a $121 million Series B financing. The Series B was led by new investor Bessemer Venture Partners with participation from other new investors, Amgen Ventures, Codon Capital, Alexandria Venture Investments, Gaingels and GC&H, as well as existing investors, Timothy A. Springer, Lightspeed Venture Partners, Polaris Partners, Boxer Capital, GV, Samsara BioCapital, and management and founders.
Proceeds from the Series B financing will be used to advance through Phase 1 proof-of-mechanism trials with Seismic’s two lead programs: a pan‑immunoglobulin (Ig) G protease sculpting (Sc) enzyme candidate (S-1117) and a PD-1 agonist:Fc gamma receptor IIb selective Dual-cell Bidirectional (DcB) antibody candidate (S-4321). In addition, the Series B will enable the continued growth of the company’s pipeline in both the IgSc and DcB product areas, beyond the lead programs. The funding will also enable the company to further expand its proprietary machine learning-enabled IMPACT platform with the development and implementation of additional cutting-edge methods to enhance biologics drug discovery in immunology. Concurrent with the financing, Andrew Hedin, MBA, biotech and healthcare partner of Bessemer Venture Partners, will join Seismic’s board of directors.
“Seismic has made impressive achievements in a short time integrating the power of machine learning with its deep drug development expertise to create two differentiated lead programs, each offering a compelling opportunity to address unmet medical needs in autoimmune diseases in a new way,” said Mr. Hedin. “We look forward to collaborating with the Seismic team to realize the full potential of its unique approach to immunology drug development, enabled by machine learning.”
Since the company’s launch and announcement of its Series A round, Seismic has advanced two programs into IND-enabling studies. This progress resulted from Seismic’s integration of leading-edge machine learning into drug development in a specific area – biologics for immunology – powered by a diverse team of drug developers and machine learning innovators. With this approach and its IMPACT platform, Seismic has rapidly engineered novel biologics with drug-like properties using multi-parameter optimization. For its lead IgSc enzyme program, Seismic engineered novel pan-IgG proteases with reduced B cell and T cell immunogenicity and chemical liabilities while maintaining enzyme activity and stability, creating a protease therapeutic to address multiple pathogenic mechanisms in a single drug for the treatment of acute and chronic autoantibody mediated diseases. Seismic designed its lead DcB antibody program to optimize the targeting of multiple cell types that drive pathogenesis of autoimmune diseases, specifically engaging T cells via PD-1 agonism and antigen presenting cells via the inhibitory Fc gamma receptor.
“We are delighted to secure the support of such a strong syndicate of investors who believe in Seismic’s ability to pioneer a new era of immunology drug development integrating machine learning,” said Jo Viney, PhD, Founder, President and CEO of Seismic Therapeutic. “This financing enables us to continue our momentum and advance both of our exciting lead programs into the clinic. We believe the time is right to harness advances in machine learning to discover the next generation of biologics drugs to improve the lives of patients with autoimmune diseases.”
About the IMPACT Platform
The IMPACT platform “parallelizes” interdisciplinary components of drug discovery to generate drug molecules on an unprecedented scale that are engineered to be better therapeutics to treat autoimmune diseases. Comprehensive integration of machine learning with protein engineering, structural biology and translational immunology enables the accelerated design and analysis of vast numbers of proteins and protein modifications. This parallelized process bypasses the trial and error methods of conventional biologics development, enabling simultaneous optimization for biologic function, reduced immunogenicity and developability, resulting in the creation of novel biologics with superior properties.
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X (formerly Twitter) @Seismic_Tx.
About Bessemer Venture Partners
Bessemer Venture Partners helps entrepreneurs lay strong foundations to build and forge long-standing companies. With more than 145 IPOs and 300 portfolio companies in the enterprise, consumer and healthcare spaces, Bessemer supports founders and CEOs from their early days through every stage of growth. Bessemer’s global portfolio has included Pinterest, Shopify, Twilio, Yelp, LinkedIn, PagerDuty, DocuSign, Wix, Fiverr, and Toast and has $20 billion of assets under management. Bessemer has teams of investors and partners located in Tel Aviv, Silicon Valley, San Francisco, New York, London, Hong Kong, Boston, and Bangalore. Born from innovations in steel more than a century ago, Bessemer’s storied history has afforded its partners the opportunity to celebrate and scrutinize its best investment decisions (see Memos) and also learn from its mistakes (see Anti-Portfolio).
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Cambridge, Mass., October 11, 2023 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced that the company will participate in several upcoming scientific and industry meetings in Q4 2023, highlighting the company’s proprietary approach to applying machine learning to biologics drug discovery for immunology, and its emerging pipeline of novel therapeutics to treat dysregulated adaptive immunity.
“We look forward to sharing our progress at upcoming scientific meetings, presenting on a range of topics that describe the innovation of our IMPACT platform to usher in a new era of immunology drug development that integrates machine learning, as well as the advancement of our preclinical programs,” said John Sundy, MD, PhD, Chief Medical Officer and Head of R&D of Seismic Therapeutic. “Leveraging our IMPACT platform, we are building a pipeline of novel enzyme and antibody programs focused on addressing the unmet needs in autoimmune diseases to have a broad impact on patients.”
Details of the presentations and poster sessions by members of the Seismic team are as follows:
Thursday, October 12
QSP (Quantitative Systems Pharmacology) Summit
Presentation: Preclinical modeling of an IgG cleaving enzyme: A solution to a unique problem
Presenter: Alex Pellerin, PhD, Director of Preclinical Development
Time: 9:00 a.m. ET
Location: Cambridge, MA
Sunday, October 15
International Conference of the Inflammation Research Association
Keynote Address: New approaches for treating dysregulated adaptive immunity
Presenter: Jo Viney, PhD, President and Chief Executive Officer
Time: 6:30 p.m. MT
Location: Fort Collins, CO
Wednesday, November 15
PEGS Europe – Protein & Antibody Engineering Summit
Presentation: Integration of Machine Learning, Structural Biology, and Wet Lab Data to Augment Drug Discovery for Autoimmune Diseases
Presenter: Nathan Higginson-Scott, PhD, Chief Technology Officer
Session: Machine Learning for Protein Engineering, Part 1
Time: 5:30 p.m. Western European Time
Location: Lisbon, Portugal
Thursday, December 14 and Friday-Saturday, December 15-16
Antibody Engineering and Therapeutics
Presentation: Dual-cell Bidirectional (DcB) Antibodies for Targeting Multiple Inhibitory Pathways for Controlling Inflammation
Presenter: Jyothsna Visweswaraiah, PhD, Director, Biotherapeutics Drug Creation
Session: Track 1, Novel Bispecifics, Multi-specifics and Therapeutic Combinations
Time: 5:45 – 6:15 p.m. PT
Poster: Design and screening of FcγRIIb selective Fc domains to enhance checkpoint agonism and treat immune mediated diseases
Author: Allison Colthart, PhD, Principal Scientist Drug Creation
Location: San Diego, CA
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X (formerly Twitter) @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Cambridge, Mass., September 21, 2023 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced that it has been named as one of the Endpoints 11 most promising private biotechnology companies of 2023. Seismic has been chosen by the Endpoints News editorial team because of the company’s strengths in science, leadership, financial backers and opportunity to move the dial on the development of new medicines for patients with autoimmune diseases.
“We are honored to be recognized as an Endpoints 11 company, and this serves as a testament to the hard work and dedication of our entire team,” said Jo Viney, PhD, Co-Founder, President and CEO of Seismic Therapeutic. “This recognition further energizes our Seismonauts to strive to make an impact in the biotechnology industry and in our communities. We believe that by applying machine learning to immunology biologics drug discovery we are paving the way to creating positive change in the autoimmune landscape and the lives of patients.”
The 2023 Endpoints 11 winners were announced at an awards gala held at the State Room in Boston on Wednesday, September 20, 2023.
With the company’s innovative IMPACT platform integrating machine learning with biologics drug discovery, Seismic is building a pipeline of novel enzymes and antibodies to address unmet medical needs for diseases involving humoral immunity and cell-mediated immunity, the two arms of the adaptive immune system. Within 18 months since launching, Seismic’s two lead drug programs are in IND-enabling studies, each with potential to improve the treatment landscape in autoimmune diseases:
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X (formerly Twitter) @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Nine poster presentations support immunoglobin sculpting enzyme and dual-cell bidirectional antibody programs to control dysregulated adaptive immunity
Cambridge, Mass., June 14, 2023 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced nine poster presentations supporting the company’s emerging pipeline of novel biologics derived from its proprietary IMPACT platform to treat autoimmune diseases at the 23rd Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS) taking place on June 20-23 in Boston, MA. Seismic’s immunoglobin (Ig) sculpting enzymes and dual-cell bidirectional (DcB) antibody programs will be highlighted in these presentations, demonstrating the design of therapeutics to address unmet medical needs for diseases involving dysregulation of humoral immunity and cell-mediated immunity, the two arms of the adaptive immune system. In particular, results from novel in vitro human assays to characterize inhibitory checkpoint receptor agonism will be presented along with activity readouts in in vivo humanized mouse models with Seismic’s lead DcB antibody program, in comparison to current benchmarks.
“We are thrilled to share preclinical data showing rapid advancement of our Ig sculpting enzymes and DcB antibody programs and highlighting the translational immunology capabilities within our IMPACT platform,” said Kevin Otipoby, PhD, Senior VP Immunology of Seismic Therapeutic. “There is a great need for optimized treatments of dysregulated adaptive immunity and our IMPACT platform enables us to efficiently design, optimize, and select novel biologics drug candidates to address acute and chronic autoantibody mediated diseases and cell-mediated autoimmune diseases.”
Details of the poster presentations at FOCIS 2023 are as follows:
DcB Antibody Programs
IMPACTing Autoimmunity Through Dual Targeting of Antigen Presenting Cells and T Cells via Inhibitory Receptor Agonism
Tuesday, June 20th 6:00 – 7:45 p.m.
Poster number: Tu139
Author: Stephanie Grebinoski, PhD
Identification and Characterization of Selective FcγRIIb Binders and their Potential of IMPACTing Immune-Mediated Diseases
Tuesday, June 20th 6:00 – 7:45 p.m.
Poster number: Tu133
Author: Stephen Lutz, BS
Identification and Characterization of Inhibitory Receptor Agonists for the Treatment of Autoimmune and Inflammatory Diseases
Tuesday, June 20th 6:00 – 7:45 p.m.
Poster number: Tu132
Author: Michael Cianci, MS
In vivo models supporting the identification of novel inhibitory receptor agonists for the treatment of immune-mediated diseases
Tuesday, June 20th 6:00 – 7:45 p.m.
Poster number: Tu130
Author: Minasri Borah, MS
Ig Sculpting Enzyme Programs
The Promise of Machine Learning: Using Seismic’s IMPACT Platform to Design IgG Cleaving Enzymes for Chronic Treatment of Autoimmune Diseases
Thursday, June 22nd 7:30 a.m. -.7:30 p.m.
Poster number: Th143
Author: Alex Pellerin, PhD
In Vitro Assay Development to Assess Successful Removal of T and B Cell Epitopes Through Seismic’s IMPACT Platform
Wednesday, June 21st 7:30 a.m. – 7:30 p.m.
Poster number: W138
Author: Andita Newton, MS
In Vivo PK/PD Assessment of Invisibilized IgG Cleaving Protease for Chronic Treatment of Autoimmune Diseases
Tuesday, June 20th 6:00 – 7:45 p.m.
Poster number: Tu142
Author: Liliana Sanmarco, PhD
Identifying Next Generation Ig Selective Cleaving Enzymes for Treatment of Autoimmune Diseases Using IMPACT Platform
Tuesday, June 20th 6:00 – 7:45 p.m.
Poster number: Tu134
Author: Purvi Mande, PhD
High-Throughput Western Blot for In Vitro and In Vivo Assessment of Human Ig Specific Cleaving Enzymes
Tuesday, June 20th 6:00 – 7:45 p.m.
Poster number: Tu126
Author: Nam Le, BS
In addition to the poster presentations, Ivan Mascanfroni, PhD, Senior Director of Immunology at Seismic, will chair the “Adaptive Immunity” session on Friday, June 23rd at 8 a.m.
About Dual-cell Bidirectional (DcB) Programs
Seismic’s DcB antibody approach targets dysregulated cell-mediated immunity by optimally engaging both T cells and antigen presenting cells, such as B cells, to restore homeostasis. Activating these pathways may control multiple diseases, such as multiple sclerosis, lupus and rheumatoid arthritis. DcB antibodies simultaneously engage multiple inhibitory pathways in more than one immune cell type thereby targeting and regulating both sides of the immune synapse.
About Immunoglobulin (Ig) Sculpting Programs
Seismic’s Ig sculpting enzymes address dysregulated humoral immunity by reducing both Ig levels and antibody effector functions, which contribute to the pathogenesis of a wide range of autoimmune diseases, such as myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and immune thrombocytopenia. Enzymes that specifically cleave antibodies may eliminate circulating and immune-complexed Ig, as well as cell surface B cell receptors, thereby modulating Ig-mediated autoimmunity and inflammation.
About Seismic Therapeutic
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to address adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow up on Twitter @Seismic_Tx and on LinkedIn.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
This links to an external website.